Shares of Eli Lilly (LLY) and Novo Nordisk (NVO) moved lower after Bloomberg reported that a Congressional Budget Office analyst said at a conference that the cost of obesity drugs would cost the U.S. more than anticipated savings. The analyst says medical coverage of obesity drugs would raise the U.S. deficit over a 10 year period, according to Bloomberg.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- J.P. Morgan Pounds the Table on Eli Lilly Stock
- Eli Lilly Stock (NYSE:LLY): Bullish on Innovation and Pharmaceutical Success
- Oprah to host TV special discussing weight loss, CNN reports
- Eli Lilly’s (NYSE:LLY) Weight-Loss Drug Outshines Wegovy for First Time
- JPMorgan biotech/pharma analysts hold an analyst/industry conference call
